Leading investigators affiliated with US Oncology Research involved in three oral clinical study presentations and ten posters
The Woodlands, Texas (October 11, 2013) - Eleven leading investigators affiliated with US Oncology Research participated in 13 major clinical studies that were featured in either oral presentations or posters at the European Society for Medical Oncology (ESMO) 2013 European Cancer Congress held September 27 through October 1 in Amsterdam. The annual event is a multi-disciplinary and multi-professional educational opportunity in oncology that takes place in Europe and plays a major role in establishing European standards for cancer treatment.
Nicholas Vogelzang, M.D., medical oncologist and cancer researcher with Comprehensive Cancer Centers of Nevada, an affiliate of US Oncology Research and The US Oncology Network, was involved with two studies that were featured in oral presentations. He was lead author and oral presenter of a major study focusing on prostate cancer titled, "Analysis of circulating tumor cells (CTCs) in a phase 3 study of docetaxel and prednisone (DP) with or without lenalidomide (LEN) in patients (pts) with castrate-resistant prostate cancer (CRPC): the MAINSAIL trial." This important study found that high circulating tumor cell (CTC) counts were related to lower overall survival (OS), suggesting that elevated CTC counts are a prognostic factor for OS and that rising CTC counts may predict both OS and poor response to docetaxel.
Dr. Vogelzang was co-investigator in another study featured in an oral presentation titled, "Phase 3 trial of dovitinib vs sorafenib in patients with metastatic renal cell carcinoma after 1 prior VEGF pathway-targeted and 1 prior mTOR inhibitor therapy." He also gave a symposium presentation titled, "Investigating the Management of mRCC in 2013: Which Way Forward?"
Daniel Von Hoff, M.D., F.A.C.P., chief scientific officer for US Oncology Research, co-authored a study featured as an oral presentation. Titled, "Molecular profiling of cancers of unknown primary site (CUP): Paradigm shift in management of CUP," the study looked at the significance of a tumor's biology versus a tumor's primary site.
Several other US Oncology Research affiliated investigators co-authored studies presented as posters at the conference:
- “A community-based, real-world, study of treatment-naïve advanced melanoma (AM) patients treated with 3 mg/kg ipilimumab (IPI) in the United States.”
D. Patt, S.L. Wong, T. Juday, J.R. Penrod, C.Chen, T. Hebden
- “Outcomes with different sequences of cabazitaxel and abiraterone acetate following docetaxel in metastatic castration-resistant prostate cancer (mCRPC).”
G. Sonpavde, M. Bhor, D. Hennessy, D. Bhowmik, L. Shen, L. Nicacio, D. Rembert, M. Yap, R. Dhanda, I. Schnadig
- “Evaluation of tolerability and anti-tumor activity of GDC-0032, a PI3K inhibitor with enhanced activity against PIK3CA mutant tumors, administered to patients with advanced solid tumors.”
D. Juric, J.R. Infante, I.E. Krop, C. Kurkjian, M.R. Patel, R.A. Graham, T.R. Wilson, J.Y. Hsu, J. Baselga, D.D. Von Hoff
- “Positron emission tomography (PET) response from a randomized phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) vs G alone for patients (pts) with metastatic adenocarcinoma of the pancreas.”
R.K. Ramanathan, D.D. Von Hoff, M. Moore, L. Teixeira, S. Siena, J. Tabernero, D. Goldstein, X. Wei, B. Lu
- “Evaluation of peripheral neuropathy in a phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) vs G alone for patients with metastatic adenocarcinoma of the pancreas.”
D. Goldstein, D.D. Von Hoff, M. Moore, E. Greeno, P. Ritch, G. Tortora, R.K. Ramanathan, J. Tabernero, A. Ko, B. Lu
- “Dose delivery in a phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) vs G alone for patients with metastatic adenocarcinoma of the pancreas.”
W. Scheithauer, D.D. Von Hoff, R.K. Ramanathan, M. Moore, J. Tabernero, D. Goldstein, P. Hammel, V. Kunzmann, A. Ko, A. Romano
- “Hematologic safety of radium-223 dichloride (Ra-223) in the phase 3 ALSYMPCA trial in castration-resistant prostate cancer (CRPC) patients with bone metastases: Baseline prognostic factor subgroup analysis.”
J. O'Sullivan, D.C. Johannessen, A. Widmark, I. Syndikus, N. James, M. Dall'Oglio, I. Haugen, A. Cross, J. Garcia-Vargas, N. Vogelzang
- “Metastatic disease detection is an important cause of screen failures in a phase II trial evaluating the optimal sequence of androgen deprivation therapy and sipuleucel-T in hormone-naive patients with biochemically-recurrent prostate cancer (BRPC).”
A. Kibel, C. Drake, E. Yu, G. Adams, L. Karsh, A. Elfiky, N. Vogelzang, N. Shore, R. Tyler, E. Antonarakis
- “Characterizing prior nephrectomy patients with metastatic renal cell carcinoma (mRCC) treated with first-line sunitinib versus interferon-alfa.”
R.A. Figlin, T.E. Hutson, P. Tomczak, M.D. Michaelson, G.A. Bjarnason, X. Lin, S. Pitman Lowenthal, B. Korytowsky, E. Matczak, S. Oudard
- “Treatment sequencing following first-line sunitinib in patients (pts) with advanced renal cell carcinoma (RCC).”
M.E. Gore, T.E. Hutson, X. Lin, B. Korytowsky, M.J. Lechuga, E. Matczak, R.A. Figlin, R. Bukowski, R.J. Motzer
Many physicians affiliated with US Oncology Research, supported by McKesson Specialty Health and The US Oncology Network, are involved in conducting Health Economic Outcomes Research. Under the leadership of Debra Patt, M.D., M.P.H., medical director for the McKesson Specialty Health Healthcare Informatics and Health Economic Outcomes Research and oncologist with Texas Oncology, physicians work closely with seasoned outcomes researchers to leverage McKesson Specialty Health's unique data assets, such as its award-winning iKnowMed electronic health record system, to answer important questions related to real-world treatment effectiveness.
Under the leadership of Dr. Von Hoff and Dr. Steve Jones, medical director for US Oncology Research, as well as a team of research committees, US Oncology Research is one of the largest community-based research programs in the United States. Numerous clinical studies led by US Oncology Research affiliated physicians have been prominently featured at conferences held around the world, including the annual meeting for the American Society of Clinical Oncology (ASCO), the American Society of Hematology (ASH) Annual Meeting and Exposition and the San Antonio Breast Cancer Symposium (SABCS). From January to October 2013, 100 independent registration and investigator-initiated studies were published in peer reviewed journals by investigators associated with US Oncology Research and/or The US Oncology Network. These studies featured forward looking clinical research topics that are helping advance cancer care today and discover improved therapies for the cancer care of tomorrow.
For more information or to interview an investigator, contact US Oncology Research Public Relations Manager, Claire Crye at 281-863-6783.
About US Oncology Research
Supported by McKesson Specialty Health and The US Oncology Network, US Oncology Research draws from a network of experienced investigators and dedicated clinical staff who specialize in Phase I through Phase IV oncology clinical trials. US Oncology Research serves approximately 80 research sites and nearly 225 locations managing about 225 active trials at any given time. Physicians in the research network have enrolled more than 56,000 patients in nearly 1,300 trials since inception in 1992 and have contributed to the development of 46 cancer therapies approved by the FDA. For more information call (800) 482-6700 or visit www.usoncology.com/oncologists.
PR Contact
Contact Public Relations